Zobrazeno 1 - 10
of 88
pro vyhledávání: '"N. Rudi"'
Publikováno v:
International Journal of Infectious Diseases, Vol 101, Iss , Pp 289- (2020)
Externí odkaz:
https://doaj.org/article/cd0ce254aad84336aa2c3e9b069b24af
Autor:
J. Sánchez-Manubens, A. Gelman, N. Franch, S. Teodoro, J. R. Palacios, N. Rudi, J. Rivera, J. Antón
Publikováno v:
BMC Pediatrics, Vol 17, Iss 1, Pp 1-3 (2017)
Abstract Background Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology. Intravenous immunoglobulin (IVIG) is an effective treatment and decreases the risk of cardiac complications to less than 5%. In spite of its e
Externí odkaz:
https://doaj.org/article/8e2b1d7f9b124e55b4736e0b59aa6abb
Autor:
M Cano Alonso, A Planas-Giner, N Almendros-Abad, A Sosa-Pons, L Cardona Roca, L Coronel Cordero, M Roig Soronellas, N Rudi Sola
Publikováno v:
Section 6: Education and research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6a7ce8e297cb4b7d0b924b0a360a9f9
https://doi.org/10.1136/ejhpharm-2023-eahp.348
https://doi.org/10.1136/ejhpharm-2023-eahp.348
Autor:
Serres, M. Cabré *, Sola, N. Rudi, García, C. Pontes, Gómez, M. Vergara, Uribe, I. Parra, Torner, M. Q. Gorgas
Publikováno v:
In Farmacia Hospitalaria May-June 2014 38(3):162-168
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a28ff1ed316f94e1a2cc7a376ea61af8
https://doi.org/10.1136/ejhpharm-2022-eahp.396
https://doi.org/10.1136/ejhpharm-2022-eahp.396
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acae656455170a7afb83577dacdd2990
https://doi.org/10.1136/ejhpharm-2022-eahp.151
https://doi.org/10.1136/ejhpharm-2022-eahp.151
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Janus kinases (JAK) inhibitors, baricitinib and tofacitinib, have emerged as an effective class in the treatment of rheumatoid arthritis (RA), which when administered orally offer an alternative to subcutaneous or intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c81888f924688868693edec639692ba
https://doi.org/10.1136/ejhpharm-2021-eahpconf.159
https://doi.org/10.1136/ejhpharm-2021-eahpconf.159
Autor:
A Sosa-Pons, P Monzó Gallo, R Rodriguez Mauriz, N Rudi Sola, AA Villagrasa Vilella, L Borràs Trias, N Almendros-Abad
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Human serum albumin (HSA) is widely used in clinical practice, although many indications are still being debated. Aim and objectives To analyse the clinical indications for HSA and the level of evidence for them. Material an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4288db5f0da84adf3475d244c18195be
https://doi.org/10.1136/ejhpharm-2021-eahpconf.59
https://doi.org/10.1136/ejhpharm-2021-eahpconf.59
Autor:
N Rudi Sola, D Ferrandez Marti, S Mendiola Garcia, V Charques Trallero, C Seguí Solanes, A Retamero Delgado
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Anti-interleukin-17 (IL-17) drugs are a new option for treating patients with psoriasis which have demonstrated high efficacy in clinical trials. Aim and objectives To analyse the effectiveness of anti-IL-17 drugs for psoria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f71a7b0a9a6a6a3f285d440132fb39e
https://doi.org/10.1136/ejhpharm-2020-eahpconf.125
https://doi.org/10.1136/ejhpharm-2020-eahpconf.125
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.